GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (XBRU:ARGX) » Definitions » Net Income Including Noncontrolling Interests

argenx SE (XBRU:ARGX) Net Income Including Noncontrolling Interests : €-303 Mil (TTM As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is argenx SE Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

argenx SE's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2024 was €-57 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 was €-303 Mil.

argenx SE Net Income Including Noncontrolling Interests Historical Data

The historical data trend for argenx SE's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Net Income Including Noncontrolling Interests Chart

argenx SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only -163.09 -500.15 -361.32 -669.86 -270.56

argenx SE Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -26.97 -87.10 -68.07 -90.94 -56.67

argenx SE Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-303 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

argenx SE Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of argenx SE's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE (XBRU:ARGX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (XBRU:ARGX) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
XBRU:UCB XBRU:TUB XBRU:HYL XBRU:ONWD XBRU:ALIMG XBRU:CYAD XBRU:BIOS XBRU:OXUR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 BNTX BGNE SZSE:300122 ALNY
Traded in Other Exchanges
ARGX:USA ARGX:Mexico ARGXb:UK 0QW0:UK 1AEA:Germany 1AE:Germany 1AE:Germany A1RG34:Brazil ARGX:Austria
Address
Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Website
https://www.argenx.com
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.